Trial Profile
Renoprotective effects of azelnidipine in hypertensive diabetic patients in Mie
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Nov 2012
Price :
$35
*
At a glance
- Drugs Azelnidipine (Primary) ; Trichlormethiazide (Primary) ; Amlodipine; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms RANDAM
- 04 Oct 2012 Primary endpoint 'Urinary-albumin:creatinine-ratio' has been met.
- 04 Oct 2012 Results presented at the 24th Scientific Meeting of the International Society of Hypertension.
- 06 Apr 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.